Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Durvalumab 可延长总生存期，而放射剂量递增 > 66 Gy 可改善不可切除的 III 期非小细胞肺癌的长期局部控制：奥地利放射肿瘤肺癌研究协会登记处 (ALLSTAR) 的最新分析
期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17091443
Zehentmayr, Franz; Feurstein, Petra; Ruznic, Elvis; Langer, Brigitte; Grambozov, Brane; Klebermass, Marisa; Hochreiter, Alexandra; Purevdorj, Ayurzana; Gruber, Georg; Minasch, Danijela; Breitfelder, Barbara; Steffal, Claudia; Kirchhammer, Karoline; Stranzl, Heidi; Röder, Falk; Dieckmann, Karin
